Elsevier

Tuberculosis

Volume 94, Issue 2, March 2014, Pages 183-185
Tuberculosis

Opinion
Curing TB with open science

https://doi.org/10.1016/j.tube.2013.10.002Get rights and content

Summary

There are many funded efforts going on focused on tuberculosis research and drug or vaccine development. There is little if any global coordination or collaboration and subsequently there are likely to be huge data silos and duplication of efforts. We now propose steps to remedy this by fostering more open science in TB research.

Section snippets

Ethical approval

Not required.

Funding

None.

Competing interests

SE is a consultant for Collaborative Drug Discovery, Inc. and works on projects funded by BMGF, NIH, and FP7.

Acknowledgments

We gratefully acknowledge our colleagues Dr. Joel S. Freundlich (Rutgers University) and Alex M. Clark (Molecular Materials Informatics) for helpful discussions.

References (31)

  • A. Bingham et al.

    Competitive collaboration in the pharmaceutical and biotechnology industry

    Drug Disc Today

    (2009)
  • E.L. Ponder et al.

    Computational models for neglected diseases: gaps and opportunities

    Pharm Res

    (2013)
  • J.H. Grosset et al.

    New drugs for the treatment of tuberculosis: hope and reality

    Int J Tuberc Lung Dis

    (2012)
  • S. Ekins et al.

    Combining computational methods for hit to lead optimization in Mycobacterium tuberculosis drug discovery

    Pharm Res

    (2013)
  • L. Ballell et al.

    Fueling open-source drug discovery: 177 small-molecule leads against tuberculosis

    ChemMedChem

    (2013)
    • View full text
    Copyright © 2013 Elsevier Ltd. All rights reserved.